Statistics for Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer
Total visits
| views | |
|---|---|
| Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer | 78 |
Total visits per month
| views | |
|---|---|
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 0 |
File Visits
| views | |
|---|---|
| cancers-13-04074.pdf | 42 |
Top country views
| views | |
|---|---|
| United States | 48 |
| Portugal | 7 |
| China | 5 |
| Ireland | 5 |
| Germany | 4 |
| Australia | 3 |
| Argentina | 2 |
| Mongolia | 2 |
| Canada | 1 |
| United Kingdom | 1 |
Top city views
| views | |
|---|---|
| Lisbon | 2 |